Paul Cossum
Directeur/Bestuurslid bij Pivotal BioSciences, Inc.
Profiel
Paul Cossum is currently a Director at Pivotal BioSciences, Inc. He previously worked as the Chief Executive Officer at Proacta, Inc., Director-Preclinical Development at Ionis Pharmaceuticals, Inc., Scientist at Genentech, Inc., Vice President-Research & Development at Aronex Pharmaceuticals, Inc., and Executive Vice President-Drug Development at NewBiotics, Inc. From 2014 to 2017, he was the Executive Vice President-Research & Development at ESSA Pharma, Inc. He also served as the President of Texas BioAlliance and Chief Science Officer at Global BioDevelopment LLC.
Dr. Cossum received his undergraduate, graduate, and doctorate degrees from the University of Tasmania.
Actieve functies van Paul Cossum
| Bedrijven | Functie | Begin |
|---|---|---|
Pivotal BioSciences, Inc.
 Pivotal BioSciences, Inc. BiotechnologyHealth Technology Pivotal BioSciences, Inc. operates as an early-stage company which engages in the development and commercialization of cancer therapies. Its product pipeline includes PB 101, PB 103 and PB 105. The company was founded by Alan Epstein, Francis S. Markland, Jr. and Dimitri S. Villard in 1998 and is headquartered in Los Angeles, CA. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Paul Cossum
| Bedrijven | Functie | Einde |
|---|---|---|
| ESSA PHARMA INC. | Corporate Officer/Principal | 01-07-2017 |
| Texas BioAlliance | President | - |
Global BioDevelopment LLC
 Global BioDevelopment LLC Pharmaceuticals: MajorHealth Technology Global BioDevelopment LLC offered formulation development, immunoassay, antibody, chromatography, efficacy testing, and toxicology services. The company was founded by Michael Lewandowski and was headquartered in Clearwater, FL. | Hoofd Techniek/Wetenschap/O&O | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | - |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Paul Cossum
| University of Tasmania | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| ESSA PHARMA INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Aronex Pharmaceuticals, Inc.
 Aronex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aronex Pharmaceuticals, Inc. develops proprietary medicines to treat cancer and infectious diseases. The company's products include Nyotran, Atragen, Annamycin, and Zintevir. It is headquartered in The Woodlands, TX. | Health Technology |
NewBiotics, Inc.
 NewBiotics, Inc. Pharmaceuticals: MajorHealth Technology NewBiotics, Inc. develops pharmaceutical drugs to treat cancer and infectious disease. It applies its Enzyme Catalyzed Therapeutic Activation technology to develop pharmaceuticals that transform drug resistance into therapeutic advantage. The company was founded by H. Michael Shepard and Geoffrey Myles Wahl in 1997 and is headquartered in San Diego, CA. | Health Technology |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
| Texas BioAlliance | |
Global BioDevelopment LLC
Global BioDevelopment LLC Pharmaceuticals: MajorHealth Technology Global BioDevelopment LLC offered formulation development, immunoassay, antibody, chromatography, efficacy testing, and toxicology services. The company was founded by Michael Lewandowski and was headquartered in Clearwater, FL. | Health Technology |
Pivotal BioSciences, Inc.
Pivotal BioSciences, Inc. BiotechnologyHealth Technology Pivotal BioSciences, Inc. operates as an early-stage company which engages in the development and commercialization of cancer therapies. Its product pipeline includes PB 101, PB 103 and PB 105. The company was founded by Alan Epstein, Francis S. Markland, Jr. and Dimitri S. Villard in 1998 and is headquartered in Los Angeles, CA. | Health Technology |
